90434-16-5

Basic information

• Product Name: 1-(BROMOMETHYL)-2-METHOXY-4-NITROBENZENE
• Synonyms: 1-(BROMOMETHYL)-2-METHOXY-4-NITROBENZENE
• CAS NO: 90434-16-5
• Molecular Formula: C₈H₈BrNO₃
• Molecular Weight: 246.06
• Mol File: 90434-16-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(BROMOMETHYL)-2-METHOXY-4-NITROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(BROMOMETHYL)-2-METHOXY-4-NITROBENZENE(90434-16-5)
• EPA Substance Registry System: 1-(BROMOMETHYL)-2-METHOXY-4-NITROBENZENE(90434-16-5)

Safety Data

• Hazardous Substances Data: 90434-16-5(Hazardous Substances Data)

Usage

Description

1-(Bromomethyl)-2-methoxy-4-nitrobenzene, with the molecular formula C8H8BrNO3, is a yellow solid chemical compound. It is insoluble in water but soluble in organic solvents. 1-(BROMOMETHYL)-2-METHOXY-4-NITROBENZENE is known for its utility in organic synthesis and pharmaceutical applications.

Uses

Used in Organic Synthesis:
1-(Bromomethyl)-2-methoxy-4-nitrobenzene is used as a reagent for the introduction of the bromomethyl group into other molecules. Its ability to facilitate the formation of new carbon-carbon bonds makes it a valuable tool in creating a variety of organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(Bromomethyl)-2-methoxy-4-nitrobenzene is utilized for the production of various drugs. Its unique structure allows for the development of molecules with specific therapeutic properties.
Used in Chemical Research:
Due to its potential mutagenicity and carcinogenicity, 1-(Bromomethyl)-2-methoxy-4-nitrobenzene is also used in chemical research to study the effects of nitro and bromo substituents on the biological activity of molecules. This research can contribute to the understanding of the mechanisms of mutagenicity and carcinogenicity, which is crucial for the development of safer chemicals and pharmaceuticals.
Caution:

Upstream product

• 13120-77-9 2-methyl-5-nitroanisole 
• 136507-14-7 (2-methoxy-4-nitrophenyl)methanol 
• 5428-54-6 2-methyl-5-nitrophenol 

Downstream Products

• 136507-13-6 acetic acid 2-methoxy-4-nitro-benzyl ester 
• 622863-80-3 5-(benzyloxy)-2-[(E)-2-(2-methoxy-4-nitrophenyl)ethenyl]-1H-indole 
• 622858-54-2 9-hydroxy-4-(2-methoxy-4-nitrophenyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione 
• 622863-82-5 9-benzyloxy-4-(2-methoxy-4-nitro-phenyl)-4,5,6,10c-tetrahydro-3aH-pyrrolo[3,4-c]carbazole-1,3-dione 
• 622863-84-7 9-benzyloxy-4-(2-methoxy-4-nitrophenyl)pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione 
• 136507-15-8 4-nitro-2-methoxybenzaldehyde 
• 136507-14-7 (2-methoxy-4-nitrophenyl)methanol 
• 497854-58-7 (2-methoxy-4-nitrophenyl)(pyridin-2-yl)methanol 
• 497854-59-8 (4-amino-2-methoxyphenyl)(pyridin-2-yl)methanol 
• 497848-99-4 7-[4-(2-butoxyethoxy)phenyl]-N-{4-[hydroxy(1-oxidopyridin-2-yl)methyl]-3-methoxyphenyl}-2,3-dihydro-1H-1-benzazepine-4-carboxamide 
• 497854-60-1 7-[4-(2-butoxyethoxy)phenyl]-N-{4-[hydroxy(pyridin-2-yl)methyl]-3-methoxyphenyl}-1-(trifluoroacetyl)-2,3-dihydro-1H-1-benzazepine-4-carboxamide 
• 497851-46-4 7-[4-(2-butoxyethoxy)phenyl]-N-{4-[hydroxy(1-oxidopyridin-2-yl)methyl]-3-methoxyphenyl}-1-(trifluoroacetyl)-2,3-dihydro-1H-1-benzazepine-4-carboxamide 

Relevant articles and documents

Substitution Effect on 2-(Oxazolinyl)-phenols and 1,2,5-Chalcogenadiazole -Annulated Derivatives: Emission-Color-Tunable, Minimalistic Excited-State Intramolecular Proton Transfer (ESIPT)-Based Luminophores

Minimalistic 2-(oxazolinyl)-phenols substituted with different electron-donating and -withdrawing groups as well as 1,2,5-chalcogenadiazole-annulated derivatives thereof were synthesized and investigated in regard to their emission behavior in solution as well as in the solid state. Depending on the nature of the incorporated substituent and its position, emission efficiencies were increased or diminished, resulting in AIE or ACQ characteristics. Single-crystal analysis revealed J- and H-type packing motifs and a so-far undescribed isolation of ESIPT-based fluorophores in the keto form.

Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors

Transcriptional enhancer associated domain family members (TEADs) are the most important downstream effectors that play the pivotal role in the development, regeneration and tissue homeostasis. Recent biochemical studies have demonstrated that TEADs could undergo autopalmitoylation that is indispensable for its function making the lipid-binding pocket an attractive target for chemical intervention. Herein, through structure-based virtual screen and rational medicinal chemistry optimization, we identified DC-TEADin02 as the most potent, selective, covalent TEAD autopalmitoylation inhibitor with the IC50 value of 197 ± 19 nM while it showed minimal effect on TEAD-YAP interaction. Further biochemical counter-screens demonstrate the specific thiol reactivity and selectivity of DC-TEADin02 over the kinase family, lipid-binding proteins and epigenetic targets. Notably, DC-TEADin02 inhibited TEADs transcription activity leading to downregulation of YAP-related downstream gene expression. Taken together, our findings proved the validity of modulating transcriptional output in the Hippo signaling pathway through irreversible chemical interventions of TEADs autopalmitoylation activity, which may serve as a qualified chemical tool for TEADs palmitoylation-related studies in the future.

Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: Relationship between absolute configuration and subtype selectivity

Introduction of an alkylcarboxylic acid unit, which is a partial structure of endogenous peroxisome proliferator-activated receptor (PPAR) ligands, into a phenethylphenylphthalimide skeleton, which possesses liver X receptor (LXR) antagonistic activity, afforded novel PPAR ligands. The results of structure-activity relationship analysis and docking studies led us to the potent PPAR agonists 13c-e. The absolute configuration of 13c-e affects the PPAR subtype selectivity.